Wuhan Hiteck Biological Pharma Co Ltd (300683) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.008x

Based on the latest financial reports, Wuhan Hiteck Biological Pharma Co Ltd (300683) has a cash flow conversion efficiency ratio of -0.008x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-17.49 Million ≈ $-2.56 Million USD) by net assets (CN¥2.24 Billion ≈ $328.35 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Wuhan Hiteck Biological Pharma Co Ltd balance sheet independence to measure how much of total assets are equity-financed.

Wuhan Hiteck Biological Pharma Co Ltd - Cash Flow Conversion Efficiency Trend (2013–2024)

This chart illustrates how Wuhan Hiteck Biological Pharma Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Wuhan Hiteck Biological Pharma Co Ltd (300683) cash flow quality to evaluate the quality of earnings relative to operating cash generation.

Wuhan Hiteck Biological Pharma Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Wuhan Hiteck Biological Pharma Co Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Prime Energy PE Ltd TA:PRIM	-0.084x
SNT Dynamics Co Ltd KO:003570	-0.026x
Qinghai Huzhu Barley Wine Co Ltd SHE:002646	0.000x
China Haisum Engineering Co Ltd SHE:002116	0.043x
Network18 Media & Investments Limited NSE:NETWORK18	-0.016x
Lumibird SA PA:LBIRD	0.075x
Qingdao Huijintong Power SHG:603577	-0.017x
Summit Hotel Properties Inc NYSE:INN	0.035x

Annual Cash Flow Conversion Efficiency for Wuhan Hiteck Biological Pharma Co Ltd (2013–2024)

The table below shows the annual cash flow conversion efficiency of Wuhan Hiteck Biological Pharma Co Ltd from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see Wuhan Hiteck Biological Pharma Co Ltd (300683) total market value.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	CN¥2.41 Billion ≈ $352.89 Million	CN¥22.69 Million ≈ $3.32 Million	0.009x	+341.74%
2023-12-31	CN¥2.50 Billion ≈ $365.17 Million	CN¥5.31 Million ≈ $777.64K	0.002x	-90.62%
2022-12-31	CN¥2.34 Billion ≈ $341.71 Million	CN¥53.03 Million ≈ $7.76 Million	0.023x	+340.20%
2021-12-31	CN¥2.34 Billion ≈ $342.86 Million	CN¥12.09 Million ≈ $1.77 Million	0.005x	+145.17%
2020-12-31	CN¥1.72 Billion ≈ $252.41 Million	CN¥-19.70 Million ≈ $-2.88 Million	-0.011x	-131.90%
2019-12-31	CN¥1.76 Billion ≈ $257.61 Million	CN¥63.03 Million ≈ $9.22 Million	0.036x	-16.64%
2018-12-31	CN¥1.71 Billion ≈ $250.17 Million	CN¥73.42 Million ≈ $10.74 Million	0.043x	-15.06%
2017-12-31	CN¥1.64 Billion ≈ $240.44 Million	CN¥83.08 Million ≈ $12.16 Million	0.051x	-75.28%
2016-12-31	CN¥703.35 Million ≈ $102.92 Million	CN¥143.86 Million ≈ $21.05 Million	0.205x	-23.66%
2015-12-31	CN¥596.76 Million ≈ $87.32 Million	CN¥159.89 Million ≈ $23.40 Million	0.268x	+6.18%
2014-12-31	CN¥536.59 Million ≈ $78.52 Million	CN¥135.40 Million ≈ $19.81 Million	0.252x	-16.35%
2013-12-31	CN¥254.64 Million ≈ $37.26 Million	CN¥76.82 Million ≈ $11.24 Million	0.302x	--

About Wuhan Hiteck Biological Pharma Co Ltd

SHE:300683 China Drug Manufacturers - Specialty & Generic

Market Cap

$489.96 Million

CN¥3.35 Billion CNY

Market Cap Rank

#12181 Global

#3493 in China

Share Price

CN¥25.58

Change (1 day)

-0.74%

52-Week Range

CN¥23.33 - CN¥59.41

All Time High

CN¥84.19